Showing results (191-200 of 1,988) with videos related to
Sort By:
Pageof 199
Frontiers in Oncology|September 12, 2022
CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trialsHangcheng Xu, Yan Wang, Yiqun Han, et al.Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 17, 2017
Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathyJiani Wang, Qing Li, Binghe Xu, et al.Current Oncology (Toronto, Ont.)|December 22, 2022
Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-AnalysisYiqun Han, Jiayu Wang, Yun Wu, et al.Thoracic Cancer|January 25, 2024
Prognostic value and relapse pattern of HER2-low in hormone receptor-positive breast cancerTong Wei, Yikun Kang, Xue Wang, et al.Journal of the National Cancer Center|July 22, 2024
Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II studyNilupai Abudureheiyimu, Yun Wu, Qing Li, et al.Oncotarget|December 1, 2016
Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancerTongtong Zhang, Qing Li, Shanshan Chen, et al.Cancer Management and Research|October 6, 2018
Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapyYuqian Liao, Yulu Liao, Jun Li, et al.The Oncologist|April 8, 2014
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancerAndrew D Seidman, Stephen Chan, Jin Wang, et al.Frontiers in Oncology|May 28, 2021
Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han PopulationShaoyan Lin, Hongnan Mo, Yiqun Li, et al.Breast Cancer Research and Treatment|October 14, 2021
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-upFangchao Zheng, Feng Du, Wenmiao Wang, et al.Pageof 199